SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    W.-C. Hsiao, K.-S. Shia, Y.-T. Wang, Y.-N. Yeh, C.-P. Chang, Y. Lin, P.-H. Chen, C.-H. Wu, Y.-S. Chao, M.-S. Hung, A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis, Diabetes, Obesity and Metabolism, 2015, 17, 5
  2. 2
    Punit Kumar, Kashyap Kumar Dubey, Current trends and future prospects of lipstatin: a lipase inhibitor and pro-drug for obesity, RSC Adv., 2015, 5, 106, 86954

    CrossRef

  3. 3
    Bernard Le Foll, Abhiram Pushparaj, Yaroslaw Pryslawsky, Benoit Forget, Kiran Vemuri, Alexandros Makriyannis, Jose M. Trigo, Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 52, 86

    CrossRef

  4. 4
    Patricia Rivera, María Jesús Luque-Rojas, Antoni Pastor, Eduardo Blanco, Francisco J. Pavón, Antonia Serrano, Ana Crespillo, Margarita Vida, Jesús M. Grondona, Manuel Cifuentes, Francisco J. Bermúdez-Silva, Rafael la Torre, Fernando Rodríguez Fonseca, Juan Suárez, Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats, European Journal of Neuroscience, 2013, 37, 1
  5. 5
    Robert J. Chorvat, Peripherally restricted CB1 receptor blockers, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 17, 4751

    CrossRef

  6. You have free access to this content6
    M Scherma, L Fattore, V Satta, F Businco, B Pigliacampo, SR Goldberg, C Dessi, W Fratta, P Fadda, Pharmacological modulation of the endocannabinoid signalling alters binge-type eating behaviour in female rats, British Journal of Pharmacology, 2013, 169, 4
  7. 7
    David R. Janero, Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists, Expert Opinion on Emerging Drugs, 2012, 17, 1, 17

    CrossRef

  8. 8
    John C. Clapham, Central control of thermogenesis, Neuropharmacology, 2012, 63, 1, 111

    CrossRef

  9. 9
    R S Vijayakumar, Y Lin, K-S Shia, Y-N Yeh, W-P Hsieh, W-C Hsiao, C-P Chang, Y-S Chao, M-S Hung, Induction of fatty acid oxidation resists weight gain, ameliorates hepatic steatosis and reduces cardiometabolic risk factors, International Journal of Obesity, 2012, 36, 7, 999

    CrossRef

  10. 10
    Michael J. Haas, Angela D. Mazza, Norman C.W. Wong, Arshag D. Mooradian, Inhibition of Apolipoprotein A-I Gene Expression by Obesity-Associated Endocannabinoids, Obesity, 2012, 20, 4
  11. 11
    Erik B. Oleson, Joseph F. Cheer, Paradoxical effects of the endocannabinoid uptake inhibitor VDM11 on accumbal neural encoding of reward predictive cues, Synapse, 2012, 66, 11
  12. 12
    Erin B. Rasmussen, William Reilly, Jessica Buckley, & Steven R. Boomhower, Rimonabant reduces the essential value of food in the genetically obese Zucker rat: An exponential demand analysis, Physiology & Behavior, 2012, 105, 3, 734

    CrossRef

  13. 13
    David R Janero, Loren Lindsley, Venkata Kiran Vemuri, Alexandros Makriyannis, Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk, Expert Opinion on Drug Discovery, 2011, 6, 10, 995

    CrossRef

  14. 14
    Changyu Pan, Hyung Joon Yoo, Low-Tone Ho, Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia, Journal of Obesity, 2011, 2011, 1

    CrossRef

  15. 15
    John C. Clapham, Jonathan R.S. Arch, Targeting thermogenesis and related pathways in anti-obesity drug discovery, Pharmacology & Therapeutics, 2011, 131, 3, 295

    CrossRef

  16. 16
    Carmelo Quarta, Luigi Bellocchio, Giacomo Mancini, Roberta Mazza, Cristina Cervino, Luzie J. Braulke, Csaba Fekete, Rocco Latorre, Cristina Nanni, Marco Bucci, Laura E. Clemens, Gerhard Heldmaier, Masahiko Watanabe, Thierry Leste-Lassere, Marlène Maitre, Laura Tedesco, Flaminia Fanelli, Stefan Reuss, Susanne Klaus, Raj Kamal Srivastava, Krisztina Monory, Alessandra Valerio, Annamaria Grandis, Roberto De Giorgio, Renato Pasquali, Enzo Nisoli, Daniela Cota, Beat Lutz, Giovanni Marsicano, Uberto Pagotto, CB1 Signaling in Forebrain and Sympathetic Neurons Is a Key Determinant of Endocannabinoid Actions on Energy Balance, Cell Metabolism, 2010, 11, 4, 273

    CrossRef

  17. 17
    David P. Finn, Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance, Immunobiology, 2010, 215, 8, 629

    CrossRef

  18. 18
    Fabrizio Montecucco, François Mach, Atherosclerosis is an inflammatory disease, Seminars in Immunopathology, 2009, 31, 1, 1

    CrossRef

  19. 19
    David R Janero, Alexandros Makriyannis, Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis, Expert Opinion on Emerging Drugs, 2009, 14, 1, 43

    CrossRef

  20. 20
    Souzana Choussein, Angeliki A. Makri, Constantinos C. Frangos, Eleni Th. Petridou, Stella S. Daskalopoulou, Effect of antiobesity medications in patients with type 2 diabetes mellitus, Diabetes, Obesity and Metabolism, 2009, 11, 7
  21. 21
    Sandrine Lecour, Multiple protective pathways against reperfusion injury: A SAFE path without Aktion?, Journal of Molecular and Cellular Cardiology, 2009, 46, 5, 607

    CrossRef

  22. 22
    S. Petta, C. Muratore, A. Craxì, Non-alcoholic fatty liver disease pathogenesis: The present and the future, Digestive and Liver Disease, 2009, 41, 9, 615

    CrossRef

  23. 23
    I. Kyrou, C. Tsigos, Obesity in the Elderly Diabetic Patient: Is weight loss beneficial? No, Diabetes Care, 2009, 32, suppl_2, S403

    CrossRef

  24. 24
    Bernard Le Foll, David A. Gorelick, Steven R. Goldberg, The future of endocannabinoid-oriented clinical research after CB1 antagonists, Psychopharmacology, 2009, 205, 1, 171

    CrossRef

  25. 25
    André J. Scheen, Nicolas Paquot, Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders, Best Practice & Research Clinical Endocrinology & Metabolism, 2009, 23, 1, 103

    CrossRef

  26. 26
    Derek LeRoith, Case Study Responses, Insulin, 2008, 3, 3, 190

    CrossRef

  27. 27
    Arnold von Eckardstein, HDL – a difficult friend, Drug Discovery Today: Disease Mechanisms, 2008, 5, 3-4, e315

    CrossRef

  28. 28
    André J Scheen, Nicolas Paquot, Inhibitors of cannabinoid receptors and glucose metabolism, Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 4, 505

    CrossRef

  29. 29
    Esther MM Ooi, Gerald F Watts, Nutrition and metabolism: new insights into lifestyle modifications and pharmacotherapy for managing cardiometabolic risk, Current Opinion in Lipidology, 2008, 19, 6, 617

    CrossRef

  30. 30
    Other Pharmacologic Approaches,